SAFETY DATA SHEET



1. Identification

Product identifier Bamlanivimab Injection

Other means of identification

 Item Code
 702822, 702900, 702776, VL7910, 702661, 702662, 702690, CT9587

 Synonyms
 LY-CoV555 * Variant 555 * LY3819353 Injection * 3819253 Injection

LY Number LY3819253

Recommended use Pharmaceutical

Recommended restrictions None known.

Manufacturer/Importer/Supplier/Distributor information

Manufacturer

Company name Eli Lilly and Company
Address Lilly Corporate Center
Indianapolis, IN 46285

United States

Telephone Phone: +1-317-276-2000

E-mail lilly_sds@lilly.com

Emergency phone number CHEMTREC: +1-800-424-9300

2. Hazard(s) identification

Physical hazards Not classified.

Health hazards Not classified.

OSHA defined hazards Not classified.

Label elements

Hazard symbol None.
Signal word None.

Hazard statement The mixture does not meet the criteria for classification.

Precautionary statement

Prevention Not available.

Response Not available.

Storage Not available.

Disposal Not available.

Hazard(s) not otherwise

classified (HNOC)

None known.

Supplemental information None.

3. Composition/information on ingredients

Mixtures

Chemical name	Common name and synonyms	CAS number	%
Bamlanivimab		2423943-37-5	3.5

Composition comments Remaining components of this product are non-hazardous and/or are present at concentrations

below reportable levels.

4. First-aid measures

Inhalation Call a physician if symptoms develop or persist.

Skin contact Rinse skin with water/shower. Get medical attention if irritation develops and persists.

Eye contact Rinse with water. Get medical attention if irritation develops and persists.

Ingestion Get medical attention if symptoms occur.

Material name: Bamlanivimab Injection

Most important

symptoms/effects, acute and delayed

This substance is a monoclonal antibody. Based on the biophysical properties and absorption characteristics of monoclonal antibodies, this substance/preparation is considered unlikely to produce health effects through relevant routes of occupational exposures.

Indication of immediate medical attention and special treatment needed

None known.

5. Fire-fighting measures

Suitable extinguishing media

Not available.

Unsuitable extinguishing media

Specific hazards arising from the chemical

Not applicable.

Special protective equipment

Wear suitable protective equipment.

and precautions for firefighters General fire hazards

This product is an aqueous mixture which will not burn.

6. Accidental release measures

Personal precautions, protective equipment and emergency procedures

Avoid inhalation of mists or aerosols.

Methods and materials for containment and cleaning up Use absorbent/adsorbent material to solidify liquids. Clean up promptly by sweeping or vacuum.

Wear appropriate protective equipment and clothing during clean-up.

Use fire-extinguishing media appropriate for surrounding materials.

Environmental precautions Avoid release to the environment.

7. Handling and storage

Precautions for safe handling

Not available.

Conditions for safe storage, including any incompatibilities Keep container tightly closed in a dry and well-ventilated place.

8. Exposure controls/personal protection

Occupational exposure limits

Lilly (LEG) Components Value Type Bamlanivimab (CAS TWA (12hrs) 200 µg/m3 2423943-37-5)

TWA (8hrs)

No biological exposure limits noted for the ingredient(s). **Biological limit values Exposure guidelines** Health Based Excursion Limit: Maintain Full Shift TWA

Appropriate engineering controls

Contained handling practices preferred. If open handling is necessary, use control measures (i.e. ventilated enclosure, local exhaust ventilation) to maintain airborne levels below the occupational

300 µg/m3

exposure level (OEL).

Individual protection measures, such as personal protective equipment

Eye/face protection Safety glasses with side shields recommended. If splash potential or dusty operations, wear

goggles/faceshield.

Skin protection

Hand protection Chemical resistant gloves.

Other While monoclonal antibodies are not anticipated to be readily absorbed through the skin, wear

impervious gloves and body covering (i.e. lab coat) to minimize skin contact.

If the applicable occupational exposure level (OEL) is anticipated to be exceeded, wear an Respiratory protection

approved respirator with sufficient protection factor to control exposure below the OEL.

General hygiene considerations

Engineering controls should be used as the primary means to control workplace exposures. Follow good workplace hygiene practices such as washing hands after handling this material.

This substance is a monoclonal antibody. Based on the biophysical properties and absorption characteristics of monoclonal antibodies, oral and dermal routes of exposure are not considered

occupationally relevant and potential bioavailability through inhalation is minimal.

7493 Version #: 07 Revision date: 07-16-2021 Issue date: 10-13-2020

9. Physical and chemical properties

Appearance

Liquid. **Physical state**

Aqueous Solution Form Color Clear, colorless

Odor Odorless **Odor threshold** Not available. 5.5 - 6.5 pН

Melting point/freezing point Not available. Not available. Initial boiling point and boiling

range

Flash point Not available. **Evaporation rate** Not available. Flammability (solid, gas) Not applicable. Upper/lower flammability or explosive limits

Flammability limit - lower

Not available.

(%)

Flammability limit - upper

Not available.

(%)

Not available. Explosive limit - lower (%) Explosive limit - upper (%) Not available. Not available. Vapor pressure

Vapor density Not available. Relative density Not available.

Solubility(ies)

Soluble Solubility (water)

Partition coefficient Not available.

(n-octanol/water)

Not available. **Auto-ignition temperature Decomposition temperature** Not available. Not available. **Viscosity**

Other information

Explosive properties Not explosive.

Oxidizing properties No oxidizing properties.

10. Stability and reactivity

Not water reactive. Reactivity

Material is stable under normal conditions. **Chemical stability** Possibility of hazardous Hazardous polymerization does not occur.

reactions

Conditions to avoid None under normal conditions.

Incompatible materials Strong oxidizing agents.

Hazardous decomposition

products

No hazardous decomposition products are known.

11. Toxicological information

Information on toxicological effects

Based on available data, the classification criteria are not met. Acute toxicity Based on available data, the classification criteria are not met. Skin corrosion/irritation Based on available data, the classification criteria are not met. Serious eye damage/eye

irritation

Material name: Bamlanivimab Injection 7493 Version #: 07 Revision date: 07-16-2021 Issue date: 10-13-2020 Respiratory or skin sensitization

Respiratory sensitization Due to inconclusive data the classification criteria are not met. Due to inconclusive data the classification criteria are not met. Skin sensitization

Germ cell mutagenicity This substance is a monoclonal antibody. It does not possess mutagenic potential.

Mutagenicity testing has not been conducted.

Carcinogenicity Not listed by IARC, NTP, ACGIH or OSHA.

Based on available data, the classification criteria are not met.

IARC Monographs. Overall Evaluation of Carcinogenicity

Not listed.

OSHA Specifically Regulated Substances (29 CFR 1910.1001-1053)

US. National Toxicology Program (NTP) Report on Carcinogens

Not listed.

Reproductive toxicity Based on available data, the classification criteria are not met.

Specific target organ toxicity -

single exposure

Based on available data, the classification criteria are not met.

Specific target organ toxicity -

repeated exposure

Based on available data, the classification criteria are not met.

Aspiration hazard Based on available data, the classification criteria are not met.

Further information This substance is a monoclonal antibody. Based on the biophysical properties and absorption

characteristics of monoclonal antibodies, oral and dermal routes of exposure are not considered

occupationally relevant and potential bioavailability through inhalation is minimal.

12. Ecological information

Ecotoxicity Due to lack of data the classification is not possible.

Not available. Persistence and degradability Not available. Bioaccumulative potential Not available. Mobility in soil Not available. Other adverse effects

13. Disposal considerations

Dispose in accordance with all applicable regulations. **Disposal instructions**

14. Transport information

Not regulated as dangerous goods.

IATA

Not regulated as dangerous goods.

IMDG

Not regulated as dangerous goods.

Transport in bulk according to

Not available.

Annex II of MARPOL 73/78 and

the IBC Code

15. Regulatory information

US federal regulations This product is not known to be a "Hazardous Chemical" as defined by the OSHA Hazard

Communication Standard, 29 CFR 1910.1200.

Toxic Substances Control Act (TSCA)

TSCA Section 12(b) Export Notification (40 CFR 707, Subpt. D)

Not regulated.

CERCLA Hazardous Substance List (40 CFR 302.4)

Not listed.

SARA 304 Emergency release notification

Not regulated.

OSHA Specifically Regulated Substances (29 CFR 1910.1001-1053)

Not listed.

Material name: Bamlanivimab Injection

Superfund Amendments and Reauthorization Act of 1986 (SARA)

SARA 313 (TRI reporting)

Not regulated.

Other federal regulations

Clean Air Act (CAA) Section 112 Hazardous Air Pollutants (HAPs) List

Not regulated.

Clean Air Act (CAA) Section 112(r) Accidental Release Prevention (40 CFR 68.130)

Not regulated.

International Inventories

Country(s) or region On inventory (yes/no)* Inventory name Canada Domestic Substances List (DSL) Canada Non-Domestic Substances List (NDSL) No

United States & Puerto Rico Toxic Substances Control Act (TSCA) Inventory No

16. Other information, including date of preparation or last revision

10-13-2020 Issue date **Revision date** 07-16-2021

Version # 07

ACGIH: American Conference of Governmental Industrial Hygienists. List of abbreviations

> DOT: Department of Transportation (49 CFR 172.101). IARC: International Agency for Research on Cancer. IATA: International Air Transport Association. IMDG: International Maritime Dangerous Goods.

MARPOL: International Convention for the Prevention of Pollution from Ships.

NTP: National Toxicology Program.

OSHA: Occupational Safety & Health Administration.

RID: Regulations concerning the International Carriage of Dangerous Goods by Rail.

Disclaimer As of the date of issuance, we are providing available information relevant to the handling of this

material in the workplace. All information contained herein is offered with the good faith belief that it is accurate. THIS SAFETY DATA SHEET SHALL NOT BE DEEMED TO CREATE ANY WARRANTY OF ANY KIND (INCLUDING WARRANTY OF MERCHANT ABILITY OR FITNESS FOR A PARTICULAR PURPOSE). In the event of an adverse incident associated with this material, this safety data sheet is not intended to be a substitute for consultation with appropriately trained personnel. Nor is this safety data sheet intended to be a substitute for product literature

which may accompany the finished product.

For additional information contact:

Eli Lilly and Company **Hazard Communication** +1-317-651-9533

Revision information Exposure controls/personal protection: Exposure guidelines

Material name: Bamlanivimab Injection

5/5 7493 Version #: 07 Revision date: 07-16-2021 Issue date: 10-13-2020

^{*}A "Yes" indicates that all components of this product comply with the inventory requirements administered by the governing country(s) A "No" indicates that one or more components of the product are not listed or exempt from listing on the inventory administered by the governing country(s).